000			01776nam a2200277 4500
001			ESSALUD
005			20260903092258.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aMaini, Luca _eAutor _954502
245			_aMedicaid’s GENEROUS Most-Favored-Nation Pricing Model — Promise and Limitations
300			_apáginas: 1772-1774
520			_aOn November 10, 2025, the Centers for Medicare and Medicaid Services (CMS) released a request for applications seeking pharmaceutical manufacturer participation in the GENEROUS (Generating Cost Reductions for U.S. Medicaid) model — a pilot program intended to reduce Medicaid drug spending and improve drug access. Under the program, participating manufacturers will offer supplemental rebates tied to prices in non-U.S. Group of Seven (G7) countries (Canada, France, Germany, Italy, Japan, and the United Kingdom) plus Denmark and Switzerland in exchange for federally negotiated coverage criteria. State Medicaid programs will then decide whether to accept those coverage terms. Participating states will forgo any additional state-specific rebates they previously negotiated but will retain Medicaid Drug Rebate Program (MDRP) statutory rebates.
650			_aCOSTO DE LA ATENCIÓN MÉDICA _954150
650			_aMEDICAMENTOS, DISPOSITIVOS Y LA FDA _954223
650			_aMEDICARE _954503
650			_aMEDICAID _954504
650			_aIMPLEMENTACIÓN DE LA REFORMA _954441
700			_aSachs, Rachel E. _954505
700			_aKyle, Michael Anne _954506
700			_aKakani, Pragya _954507
773	0		_022717 _922676 _dMassachusetts NEJM Group _oNEJM015 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-31 _zsqb
999			_c22913 _d22913